Surprisingly, the identified aptamers recognize various cancer cells particularly those derived from solid tumours, while non-tumourgenic and primary healthy cells are not recognized.
Thus, these findings render the aptamers applicable as broad-spectrum diagnostics and therapeutics.
The described technology enables diagnosis and treatment of several tumour types with one formulation, thereby reducing the developing costs for pharmaceuticals.
On behalf of the University Bonn, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.
In case of interest we are pleased to inform you about the current patent Status.